Independent physicians aren’t “providers.” They’re doctors or physicians. The only ones who call them “providers” are insurers and bureaucrats who want them interchangeable with a chatbot or a massage therapist. Stop using their language. #healthcare

CD4+ T-cell lymphoma harboring a CAR vector Integration in TP53 after treatment with cilta-cel in a patient with RRMM #mmsm #bmtsm NEJM nejm.org/doi/full/10.10…

Infections With Bispecific Antibodies for Myeloma: Where Do We Stand Now? dailynews.ascopubs.org/do/infections-… Pankaj Malhotra Uday Yanamandra MCW Cancer Center #mmsm

Dr. Mansi Shah from Rutgers Cancer Institute highlights Venetoclax potential for t(11;14) MM, showing ORR & PFS results in trials like BELLINI & CANOVA. #Oncology #Hematology #DAVAWhistler

At the #DAVAWhistler summit, Mansi Shah from Rutgers Cancer Institute discusses Linvoseltamab, a BCMAxCD3 bispecific antibody, with updated results from the LINKER-MM1 trial. The presentation includes 21.3 months median follow-up data on efficacy and safety in R/R MM. #Hematology

#DAVAWhistler great presentation by #mansishah regarding using “pocket dex” as the first step for CRS management with bispecifics in myeloma #MMsm. Great work by James Davis, PharmD, BCOP and colleagues!

Dr. Mansi Shah from Rutgers Cancer Institute discusses key biohacks for #Bispecifics in #MultipleMyeloma: ✅ Hybrid inpatient-outpatient models ✅ Community training & patient selection ✅ Optimized step-up dosing & real-world insights for enhanced safety and access #DAVAWhistler

nature.com/articles/s4140… RW dosing patterns D0-2-4 SUD schedule was commonly used for Tec and Tal. Second SUD used in ~0.7% of cases. Long-term dosing- 1/3 of Tec doses after 3M were Q2W, and 13% were Q4W after 6M. Tal was mostly administered Q2W MCW Cancer Center #mmsm

RW #MMsm data in action! Congrats Meera Mohan Farheen Chunara on Blood Cancer Journal publication: tec & tal in 🇺🇸 myeloma patients. Bottom line: some bsAb trials still say Q1W x6 months before de-escalating to ≤Q2W. In real life: most of us don't wait this long, nor should we!

#Myeloma Paper of the Day: Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in myeloma includes higher risk of prolonged transfusion dependence for both pRBC and G-CSF us, as well as higher thrombopoietin receptor agonist use: pubmed.ncbi.nlm.nih.gov/40203191/. #mmsm

Carfilzomib for myeloma: I don’t recommend any more than 56 mg/m2 once a week Our study results show that higher doses do not offer more benefit. Sharlene Dong Rahul Banerjee, MD, FACP Gurbakhash Kaur Aimaz Afrough Murali Janakiram Blood Cancer Journal nature.com/articles/s4140…

The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma. I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will

We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab. GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series nature.com/articles/s4140… Full link- rdcu.be/eAazx

We are talking about amyloidosis today with cardiology, pathology, neurology and heme-onc colleagues! Rutgers Cancer Institute RWJBarnabas #ALAmyloid #ATTR

Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow Alex N! Meera Mohan Samer Al Hadidi, MD,MS,FACP doi.org/10.1111/bjh.70… #CNSMyeloma #mmsm Rutgers Cancer Institute RWJBarnabas

🚨Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort Congrats to Samer Al Hadidi, MD,MS,FACP Mansi Shah: 1/🧵 New data on bispecific antibodies (BsAbs) in CNS multiple myeloma (CNS-MM) — a rare, aggressive manifestation of MM with historically poor

Check our recent work: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort #mmsm Meera Mohan Mansi Shah British Journal of Haematology ➡️ onlinelibrary.wiley.com/doi/10.1111/bj… ✔️ 100% CNS response (n=6 evaluable) ✔️ 2 pts responded before CNS-directed therapy ✔️ No grade

Great #MMsm thread about excellent British Journal of Haematology article re: bsAbs for CNS myeloma - Mansi Shah Hira Mian Samer Al Hadidi, MD,MS,FACP Part of why publishing RW data are so important: easy for insurers to ignore my #MMsm training or anecdotes, but harder to ignore a peer-reviewed publication!

More options for patients with myeloma=increased access! Low CRS and minimal step up doses with linvo!

Congratulations Meera Mohan on your presentation! Shows that time limited bispecific therapy can be done!